Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications

Ala, Moein; Jafari, Razieh Mohammad; Dehpour, Ahmad Reza

doi:10.1111/fcp.12633

Cited by 34 publications

(30 citation statements)

References 178 publications

(176 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another indication to use PDE5-i (sildenafil and tadalafil) is PAH, a common cardiovascular comorbidity associated with COPD [ 114 ]. It is defined as a condition of increased pulmonary arterial resistance, which leads to an elevated pulmonary arterial pressure (>25 mmHg at rest) that endangers the heart and causes right-sided heart failure [ 115 ].…”

Section: Management Of Ed In Copd Menmentioning

confidence: 99%

Erectile Dysfunction in Men with Chronic Obstructive Pulmonary Disease

Marinelli

Lanfranco

Motta

et al. 2021

JCM

View full text Add to dashboard Cite

Erectile dysfunction (ED) seems to be a widespread sexual issue in men affected by chronic obstructive pulmonary disease (COPD). Multiple causes appear to be involved such as hormonal imbalance, smoking habit, chronic inflammation, endothelial dysfunction, chronic hypoxia, psychiatric disorders (depression and anxiety), and medications. ED can have a significant impact on COPD men and consequently on their quality of life, which is usually already compromised. Given this situation, however, pneumologists usually do not properly care for the sexuality of COPD patients especially because men can be reluctant to talk about their intimate issues. The aim of this narrative review is to briefly summarize the evidence emerging from literature and to provide a wide point of view about sexual dysfunction in COPD men.

show abstract

Section: Management Of Ed In Copd Menmentioning

confidence: 99%

Erectile Dysfunction in Men with Chronic Obstructive Pulmonary Disease

Marinelli

Lanfranco

Motta

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Interestingly, a prospective study was conducted by Demirci So, the inflammation degree would be decreased after the improvement of IIEF-5 (Ala et al, 2021;Porst et al, 2014). Apart from haematological parameter, another biomarker, named C-reactive protein (CRP), has been considered a reliable measure of clinical and subclinical inflammation (Sproston & Ashworth, 2018).…”

Section: Ta B L E 3 Quality Assessment For All the Eligible Studiesmentioning

confidence: 99%

A systematic review and meta‐analysis of the relationship between erectile dysfunction and the neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratios

Zhang

Feng

et al. 2021

Andrologia

View full text Add to dashboard Cite

Several studies were conducted to explore the association between haematological parameters and erectile dysfunction (ED), but the conclusions were contradictory with small sample size. The extensively search was conducted in PubMed, Cochrane Library and Web of science from inception to August 2021. Studies comparing the haematological parameter (at least NLR, PLR) between ED patients and healthy controls were eligible for the present meta-analysis. The differences in NLR and PLR between ED patients and healthy controls were assessed by calculating the standardised mean difference (SMD) and 95% confidence interval (95% CI). Eventually, 7 studies were remained for our meta-analysis, with a total of 929 ED patients and 737 healthy controls. For the methodological quality based on NOS, 5 studies were of high quality, scored 7, and 8. 2 studies were of moderate quality, scored 6. There were statistically significant differences in NLR values between ED patients and healthy controls, based on the pooled results (SMD: 0.53, 95% CI: 0.24-0.82). Pooled results from the 6 studies revealed that ED patients had higher PLR values than healthy controls (SMD: 0.70, 95%CI: 0.12-1.28). Our meta-analysis solidly confirmed the association between NLR, PLR and ED. Increased NLR and PLR should be independent risk factors for ED.

show abstract

“…PDE5 inhibitors (like sildena l) block the PDE5 enzyme and this inhibition relaxes the blood vessels and increases blood ow as a result (13). Sildena l is also currently used to treat pulmonary arterial hypertension (14,15). Using sildena l leads to loosening the arterial wall, increasing uterine blood ow, and, uteroplacental perfusion as a consequence (11,12).…”

Section: Introductionmentioning

confidence: 99%

The effect of sildenafil on amniotic fluid volume in cases of borderline oligohydramnios in uncomplicated pregnancies: a randomized clinical trial.

Kashanian

Eshraghi

Moslemi

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction:Low amniotic fluid volume and oligohydramnios is important issue during pregnancy and is associated with an increase in fetal and neonatal mortality and morbidity. Finding a solution to it can improve fetal and neonatal outcomes.Objective:The purpose of the present study was to evaluate the effect of sildenafil on oligohydramnios in uncomplicated pregnancies.Methods:A placebo-controlled randomized clinical trial was performed on women with oligohydramnios and gestational age of 30 to 37 weeks and singleton pregnancy. The eligible women were randomly assigned into two groups. In the intervention group, 25 mg oral sildenafil was prescribed every 8 hours in conjunction with intravenous hydration therapy with 2 liters isotonic solution (normal saline) infused within 4 hours and in the control group, placebo and hydration therapy similar to the intervention group was prescribed. Amniotic fluid volume was re-evaluated 24 hours after treatment. If at least a 20% increase in amniotic fluid volume was detected by ultrasound, the woman was discharged; otherwise, the above regimen was repeated again for the next 24 hours.Discharged patients continued to take sildenafil or placebo at the same dose and consumption of 2 liters of oral fluids per day up to 37 weeks or delivery each happened earlier. Fetal monitoring was performed using non stress test (NST) twice a week, biophysical profile, and amniotic fluid volume measurement once a week. Amniotic fluid volume and pregnancy and neonatal outcomes were compared in the two groups.Results:One hundred ninety women finished the study. There was no statistically significant difference between the two groups in terms of maternal age, body mass index (BMI), parity, live birth rate, gestational age before the intervention, amniotic fluid index, and the type of pregnancy; spontaneous or using assisted reproductive technology (ART). In undelivered women, after the intervention, the amniotic fluid index was significantly higher in the case group than the control group. The number of women, whose pregnancies continued after the third week of intervention, were higher in the sildenafil group.At the end of the sixth week after intervention, 40 women (42.1%) in the case group continued their pregnancies versus 5 women (5.3%) in the control group (P = 0.001). Cesarean section rate, neonatal intensive care unit (NICU) admission, abnormal cardiotocography, umbilical cord pH less than 7.2, and Apgar score of less than 7 in 5 minutes, were less in the intervention group than the control group. While the mean gestational age at birth and birth weight was higher in the intervention group than the control group. There was no perinatal death in both groups.Abnormal cardiotocography (CTG) (AOR= 6.3, CI95% 2.4-15.1, P< 0.001), cesarean section rate (AOR= 4.2, CI95% 2.1-8.9, P< 0.001), birth weight of less than 2500 gram (AOR= 3.3, CI95% 1.6-6.9, P= 0.001), gestational age at birth of less than 37 weeks (AOR= 3.2, CI95% 1.5-6.9, P= 0.009 ), Apgar score of less than 7 in 5 minutes (AOR= 2.6, CI95% 1.1-6.4, P=0.037), umbilical cord pH of less than 7.2 (AOR= 2.5, CI95% 1.9-6.9, P=0.064), and NICU admission (AOR= 2.5, CI95% 1.1-5.9, P=0.032) were more in the control group.The most common maternal complication in patients was headache (15.8 vs. 7.4%) and headache (12.6 vs. 5.3%) which was more in the intervention group than the control group, but not statistically significant.Conclusion:In pregnant women with oligohydramnios, sildenafil may be associated with better pregnancy outcomes.

show abstract

Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications

Cited by 34 publications

References 178 publications

Erectile Dysfunction in Men with Chronic Obstructive Pulmonary Disease

Erectile Dysfunction in Men with Chronic Obstructive Pulmonary Disease

A systematic review and meta‐analysis of the relationship between erectile dysfunction and the neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratios

The effect of sildenafil on amniotic fluid volume in cases of borderline oligohydramnios in uncomplicated pregnancies: a randomized clinical trial.

Contact Info

Product

Resources

About